This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
BMC Immunology Open Access 04 June 2022
-
Endogenous retroviruses in the origins and treatment of cancer
Genome Biology Open Access 10 May 2021
-
Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response
BMC Immunology Open Access 21 April 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weintraub, K. Take two: Combining immunotherapy with epigenetic drugs to tackle cancer. Nat Med 22, 8–10 (2016). https://doi.org/10.1038/nm0116-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0116-8
This article is cited by
-
The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
BMC Immunology (2022)
-
Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors
Clinical and Translational Oncology (2022)
-
Endogenous retroviruses in the origins and treatment of cancer
Genome Biology (2021)
-
Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response
BMC Immunology (2020)
-
Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond
Targeted Oncology (2020)